Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 2

Status

Completed 2Withdrawn 1Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 7NIH 4NETWORK 4

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 7

Conditions

Small Cell Lung Carcinoma 42Ovarian Neoplasms 33Fallopian Tube Neoplasms 15Neoplasms 12Carcinoma, Ovarian Epithelial 10Uterine Cervical Neoplasms 7Recurrence 6Neuroblastoma 5Lung Neoplasms 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Ewing 3Endometrial Neoplasms 3Uterine Cervical Dysplasia 2Sarcoma, Clear Cell 2Sarcoma 2Rhabdomyosarcoma 2Myoepithelioma 2Medulloblastoma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Hereditary Sensory and Autonomic Neuropathies 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Carcinoma 2Solid Tumours 1Solid Tumors 1Solid Tumor 1SCLC 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Topotecan × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
398 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Seagen Inc.

Phase 3 Completed
502 enrolled 18 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT02584478 2023-11-08

AL3818

Advenchen Laboratories, LLC

Phase 3 Unknown
294 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
7 enrolled 6 charts
Gynecologic

Uterine Cervical Neoplasms

NCT02866006 2022-10-12

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Cellid Co., Ltd.

Phase 1/2 Completed
32 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡